Prognostic impact of angiogenic markers in non-small-cell lung cancer is related to tumor size

Clinical Lung Cancer

Volumn 12, Issue 2, 2011, Pages 106-115

  Donnem, Tom ^a   Andersen, Sigve ^a,b   Al Saad, Samer ^a,b   Al Shibli, Khalid ^b,c   Busund, Lill Tove ^a,b   Bremnes, Roy M ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

Angiogenesis; NSCLC

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR VOLUME;

EID: 79959348456     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.005     Document Type: Article

References (32)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
2. Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer 2008; 44:2350-6.
3. Clement-Duchene C, Wakelee H. Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review. J Thorac Oncol 2010; 5: 129-39.
4. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2:795-803. (Pubitemid 37328914)
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76. (Pubitemid 36749215)
6. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74. (Pubitemid 43093963)
7. Su JL, Yang PC, Shih JY, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006; 9:209-23.
8. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454: 656-60.
9. Lindahl P, Johansson BR, Leveen P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277:242-5. (Pubitemid 27446080)
10. Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004; 23:2800-10. (Pubitemid 39013552)
11. Gualandris A, Rusnati M, Belleri M, et al. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 1996; 7:147-60. (Pubitemid 26049823)
12. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-78. (Pubitemid 40616114)
13. Donnem T, Al Saad S, Al Shibli K, et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007; 13:6649-57. (Pubitemid 350206800)
14. Donnem T, Al Saad S, Al Shibli K, et al. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008; 3:963-70.
15. Donnem T, Al Shibli K, Al Saad S, et al. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009; 4:578-85.
16. Donnem T, Al Shibli K, Al Saad S, et al. VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: inverse correlation between expression in tumor and stromal cells. Lung Cancer 2009; 63:277-83.
17. Donnem T, Al-Saad S, Al-Shibli K, et al. Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small cell lung cancer. Ann Oncol 2010; 21:223-31.
18. Donnem T, Andersen S, Al-Shibli K, et al. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte in- filtration is a strong and independent favourable prognostic factor in patients with nonsmall cell lung cancer. Cancer 2010; 116:4318-25.
19. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of theTNMstage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706-14. (Pubitemid 47357522)
20. Goldstraw P. The 7th edition of TNM in Lung Cancer: what now? J Thorac Oncol 2009; 4:671-3.
21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70. (Pubitemid 30046295)
22. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006; 51:143-58. (Pubitemid 43144358)
23. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-39. (Pubitemid 37328908)
24. Hendriksen EM. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvasc Res 2009; 77:96-103.
25. Kajita T, Ohta Y, Kimura K, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 2001; 85:255-60. (Pubitemid 32695748)
26. Niki T, Iba S, Tokunou M, et al. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000; 6:2431-9. (Pubitemid 30399212)
27. Ogawa E, Takenaka K, Yanagihara K, et al. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer 2004; 91:498-503. (Pubitemid 39093569)
28. Ohta Y, Nozawa H, Tanaka Y, et al. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2000; 119:804-13. (Pubitemid 30395479)
29. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287-95. (Pubitemid 36554699)
30. Arbiser JL. Why targeted therapy hasn't worked in advanced cancer. J Clin Invest 2007; 117:2762-5. (Pubitemid 47529607)
31. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007; 117:2766-77. (Pubitemid 47529608)
32. Krupitskaya Y, Wakelee H. Vascular endothelial growth factor pathway. J Thorac Oncol 2009; 4:S1071-3.